1. Home
  2. OTLK vs ROMA Comparison

OTLK vs ROMA Comparison

Compare OTLK & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OTLK
  • ROMA
  • Stock Information
  • Founded
  • OTLK 2010
  • ROMA 2018
  • Country
  • OTLK United States
  • ROMA Hong Kong
  • Employees
  • OTLK N/A
  • ROMA N/A
  • Industry
  • OTLK Biotechnology: Biological Products (No Diagnostic Substances)
  • ROMA Savings Institutions
  • Sector
  • OTLK Health Care
  • ROMA Finance
  • Exchange
  • OTLK Nasdaq
  • ROMA Nasdaq
  • Market Cap
  • OTLK 48.3M
  • ROMA 46.7M
  • IPO Year
  • OTLK 2016
  • ROMA 2024
  • Fundamental
  • Price
  • OTLK $1.57
  • ROMA $3.13
  • Analyst Decision
  • OTLK Strong Buy
  • ROMA
  • Analyst Count
  • OTLK 5
  • ROMA 0
  • Target Price
  • OTLK $9.60
  • ROMA N/A
  • AVG Volume (30 Days)
  • OTLK 796.7K
  • ROMA 242.0K
  • Earning Date
  • OTLK 08-13-2025
  • ROMA 08-01-2025
  • Dividend Yield
  • OTLK N/A
  • ROMA N/A
  • EPS Growth
  • OTLK N/A
  • ROMA N/A
  • EPS
  • OTLK 0.83
  • ROMA N/A
  • Revenue
  • OTLK N/A
  • ROMA $1,029,120.00
  • Revenue This Year
  • OTLK N/A
  • ROMA N/A
  • Revenue Next Year
  • OTLK $379.84
  • ROMA N/A
  • P/E Ratio
  • OTLK $1.91
  • ROMA N/A
  • Revenue Growth
  • OTLK N/A
  • ROMA N/A
  • 52 Week Low
  • OTLK $0.87
  • ROMA $0.46
  • 52 Week High
  • OTLK $9.25
  • ROMA $4.14
  • Technical
  • Relative Strength Index (RSI)
  • OTLK 40.37
  • ROMA 57.80
  • Support Level
  • OTLK $1.65
  • ROMA $2.91
  • Resistance Level
  • OTLK $2.04
  • ROMA $3.44
  • Average True Range (ATR)
  • OTLK 0.12
  • ROMA 0.30
  • MACD
  • OTLK -0.03
  • ROMA -0.03
  • Stochastic Oscillator
  • OTLK 2.13
  • ROMA 64.77

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage and overcome various business matters arising from such factors related to ESG, sustainability and climate change. it provides tailored-made sustainability solutions to meet the client's specific needs. Its mission is to provide its clients with a one-stop destination for high-quality and holistic sustainability and climate change-related consulting services to support a more sustainable, balanced and inclusive future for its clients' organizations and the world.

Share on Social Networks: